A feline calicivirus monoclonal antibody and an evaluation platform for its application in feline calicivirus disease diagnostic reagents

Monoclonal antibodies were prepared and immobilized through genetic engineering technology, combined with PCR and other detection methods, and the problem of insufficient sensitivity and specificity in the diagnosis of cat calicivirus disease was solved, and efficient and stable diagnostic effects were achieved, providing early diagnosis. Support and expand to other animal infectious diseases.

CN118655312BActive Publication Date: 2024-11-26SHANGHAI KEELING INTELLIGENT TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410796064.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-20
Publication Date
2024-11-26
Estimated Expiration
2044-06-20

AI Technical Summary

Technical Problem

The existing cat calicivirus disease diagnosis methods lack high sensitivity and specificity, are complex and time-consuming, making it difficult to achieve early and accurate detection.

Method used

Genetic engineering technology is used to prepare high-specific and high-affinity monoclonal antibodies, and immobilize them on specific materials to build an evaluation platform, verify the specificity and affinity of antibodies through Western blot, ELISA and other methods, and combine with PCR and other detection methods. Build efficient diagnostic reagents to optimize platform performance to improve diagnostic capabilities.

Benefits of technology

Achieve efficient, stable and reliable diagnosis of cat calicivirus disease, improve diagnosis accuracy and reliability, simplify the preparation and storage process of reagents, and can quickly and accurately identify target antigens, suitable for the diagnosis of other animal infectious diseases. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118655312B_ABST
    Figure CN118655312B_ABST
Patent Text Reader

Abstract

The invention provides a feline calicivirus monoclonal antibody and an evaluation platform for applying the same in a feline calicivirus disease diagnostic reagent, comprising a feline calicivirus monoclonal antibody preparation module, an antibody identification and verification module, an antibody immobilization platform module, a feline calicivirus disease diagnostic reagent preparation module and an evaluation platform construction and optimization module, wherein the feline calicivirus monoclonal antibody preparation module prepares highly specific and high-affinity antibodies through genetic engineering technology; the antibody identification and verification module ensures that the antibodies have high sensitivity and specificity; the antibody immobilization platform module fixes the antibodies on specific materials for reagent preparation; the feline calicivirus disease diagnostic reagent preparation module constructs an efficient and accurate diagnostic reagent; and the evaluation platform construction and optimization module evaluates samples. The invention has the following beneficial effects: it has high sensitivity, specificity and stability, and provides an effective tool for early diagnosis and disease monitoring of feline calicivirus disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the fields of data analysis and smart medicine, and specifically to an evaluation platform based on a feline calicivirus monoclonal antibody and its application in feline calicivirus disease diagnostic reagents. Background Art

[0002] Feline Calicivirus (FCV) is a common cat infectious pathogen that causes feline calicivirus disease, which is widespread worldwide and poses a serious threat to the health of cats. Currently, the diagnosis of feline calicivirus disease mainly relies on clinical symptoms, medical history and laboratory tests, including hematological examinations and molecular biological tests. However, the existing diagnostic methods have some limitations, such as lack of high sensitivity and specificity, complex operations and long time consumption. Therefore, there is an urgent need to develop a more accurate, rapid and simple diagnostic reagent to improve the early detection and diagnosis of feline calicivirus disease.

[0003] Based on this background, the present invention aims to provide a feline calicivirus monoclonal antibody and an evaluation platform for its application in feline calicivirus disease diagnostic reagents. By utilizing genetic engineering technology and immunological methods, highly specific and high-affinity monoclonal antibodies are prepared and fixed on specific materials to construct a stable antibody immobilization platform. Then, the prepared monoclonal antibodies are combined with other related reagents to construct feline calicivirus disease diagnostic reagents. Finally, a complete evaluation platform is constructed. By testing a large number of feline calicivirus disease samples, the performance of the platform is continuously optimized to ensure efficient, stable and reliable diagnostic capabilities in practical applications. Summary of the invention

[0004] In view of the above problems, the present invention aims to provide a feline calicivirus monoclonal antibody and an evaluation platform for its application in feline calicivirus disease diagnostic reagents.

[0005] To achieve the above-mentioned purpose, the present invention provides the following technical solutions: a feline calicivirus monoclonal antibody and an evaluation platform for its application in feline calicivirus disease diagnostic reagents, comprising a feline calicivirus monoclonal antibody preparation module, an antibody identification and verification module, an antibody immobilization platform module, a feline calicivirus disease diagnostic reagent preparation module and an evaluation platform construction and optimization module, wherein the feline calicivirus monoclonal antibody preparation module prepares highly specific and high-affinity antibodies through genetic engineering technology; the antibody identification and verification module ensures that the antibodies have high sensitivity and specificity; the antibody immobilization platform module fixes the antibodies on specific materials for reagent preparation; the feline calicivirus disease diagnostic reagent preparation module constructs efficient and accurate diagnostic reagents; and the evaluation platform construction and optimization module evaluates the samples.

[0006] Furthermore, the feline calicivirus monoclonal antibody preparation module uses genetic engineering technology to prepare highly specific and high-affinity monoclonal antibodies.

[0007] Furthermore, firstly, it is necessary to select appropriate feline calicivirus-related proteins as antigens, including surface proteins or structural proteins associated with viral infection, which are highly immunogenic. The genome of feline calicivirus has been widely studied, so a suitable gene sequence is selected for cloning and expression. Secondly, the selected feline calicivirus gene is inserted into an expression vector using recombinant DNA technology. The expression vector usually contains an appropriate promoter and terminator, as well as an appropriate host cell selection marker gene for expression. The expression vector is introduced into the host cell, and the biosynthetic mechanism of the host cell is used to express the target protein. Next, after protein expression and purification, affinity purification technology is used to purify the target protein using protein A / G agarose and metal chelate chromatography to obtain A relatively pure target protein is obtained and used to immunize mice to prepare monoclonal antibodies. Then, mice are immunized and the purified target protein is mixed with an appropriate immune adjuvant and injected into the mice to stimulate them to produce antibodies. In order to enhance the immune effect, multiple immunizations are required with intervals of several weeks or months. Next, the antiserum produced by the mice is collected. After the immunization cycle, serum samples are collected from the blood of the mice. The serum contains the polyclonal antibodies that have been stimulated to be produced. Finally, monoclonal antibodies are prepared through cell fusion technology. The B cells of the immunized mice are fused with cancer cells to form hybridoma cells. These hybridoma cells have the ability of B cells to produce antibodies and the unlimited proliferation ability of cancer cells. After screening and cultivation, hybridoma cell lines that produce monoclonal antibodies are obtained.

[0008] Furthermore, the antibody identification and validation module is to ensure that the prepared monoclonal antibodies have high sensitivity and specificity, so that they can accurately identify the target antigen and play a role in diagnostic reagents.

[0009] Furthermore, first, the prepared monoclonal antibodies were subjected to preliminary identification, including Western blot (immunoblotting) and ELISA (enzyme-linked immunosorbent assay), to verify the specific binding of the antibody to the target antigen.

[0010] In a Western blot experiment, the target protein must first be separated and transferred to a membrane, then reacted with the prepared monoclonal antibody, and the protein-antibody binding signal is detected by chemiluminescence or staining methods.

[0011] In an ELISA experiment, the target antigen is adsorbed onto a microplate and then reacted with an antibody, and the binding of the antibody is detected by enzyme-labeled secondary antibodies or substrate staining methods.

[0012] Secondly, the affinity of the antibody is measured. Affinity refers to the strength of the binding between the antibody and the antigen, which directly affects its effect in the diagnostic reagent. The present invention adopts commonly used methods including surface ion resonance and biochromatography technology, which can monitor the interaction process between the antibody and the antigen in real time, thereby accurately measuring its affinity constant (KA) and dissociation constant (KD) and evaluating the binding characteristics between the antibody and the antigen.

[0013] Then, the specificity of the antibody is evaluated. Specificity refers to the ability of the antibody to bind to the target antigen without cross-reacting with other non-specific components. In order to evaluate the specificity of the antibody, a cross-reaction experiment is required to react the antibody with related non-target antigens to observe whether a specific binding signal is generated. At the same time, tissue sections or cell line experimental models are used to further verify the specificity of the antibody.

[0014] Next, the stability test of the antibody is carried out. The stability of the antibody directly affects its service life and storage conditions in the diagnostic reagent. The present invention adopts commonly used stability tests, including thermal stability test, freeze-thaw stability test and long-term storage stability test, which can simulate the stability performance of the antibody under different environmental conditions and evaluate its reliability in practical applications.

[0015] Finally, actual sample testing and verification of the antibodies are carried out. The antibodies are tested and verified using real samples of wild-type viruses and clinical samples, and their performance in actual applications is evaluated. By comparing and analyzing with existing diagnostic methods, the accuracy and sensitivity of the antibodies in disease diagnosis are verified.

[0016] Furthermore, the antibody immobilization platform module fixes the prepared monoclonal antibody on a specific material surface to form a stable antibody immobilization platform for the preparation of diagnostic reagents for feline calicivirus disease.

[0017] Furthermore, first, a suitable immobilization material is selected. The selection of the immobilization material needs to take into account its fixation effect on the antibody, stability, biocompatibility and the convenience of the preparation process. The immobilization materials include polyvinyl alcohol, polyacrylate, glass sheet, and metal material. According to the actual needs of the reagent, a suitable immobilization material is selected for subsequent processing.

[0018] Secondly, the immobilized material is surface treated. The purpose of surface treatment is to increase the active functional groups on the surface of the immobilized material and improve the adsorption efficiency and fixation effect of the antibody. The surface treatment methods include physical adsorption, chemical cross-linking, and covalent bonding. The surface of the immobilized material is treated with chemical cross-linking agents (including nitrates, formaldehyde) or activators to have more active groups for covalent bonding with antibodies.

[0019] Next, the prepared monoclonal antibody is fixed on the surface treated immobilized material. The method of fixing the antibody is selected according to the characteristics of the immobilized material and the actual needs of the reagent. The antibody solution is directly added dropwise to the surface treated immobilized material, and the antibody is evenly adsorbed on the surface of the material by standing and rotating.

[0020] Then, the immobilized antibody was subjected to quality control and stability assessment, and its immobilization effect and stability were evaluated by testing the activity and binding efficiency of the immobilized antibody.

[0021] Finally, the preparation process of the immobilization platform was optimized according to the results of quality control and stability evaluation, and the stability of the immobilization platform was improved by adjusting the surface treatment method of the immobilized material, the antibody fixation conditions, and the stability treatment steps after immobilization.

[0022] Furthermore, the feline calicivirus disease diagnostic reagent preparation module is used to construct efficient and accurate diagnostic reagents for the detection and diagnosis of feline calicivirus disease; first, a suitable antigen is selected. The diagnostic reagent for feline calicivirus disease contains antigens related to a variety of pathogens, including feline blood-type bacilli, feline erythrozoon and feline plasmodium.

[0023] Secondly, prepare antigens, express and purify the selected antigens through genetic engineering technology and in vitro culture technology. For feline calicivirus disease diagnostic reagents, multiple antigens need to be prepared at the same time.

[0024] Next, choose a suitable detection method. The diagnostic reagents for feline calicivirus disease usually need to have high sensitivity and specificity. The detection methods include PCR (polymerase chain reaction), PCR-RFLP (PCR-Restriction Fragment Length Polymorphism), and real-time fluorescence quantitative PCR, which can quickly and accurately detect the nucleic acid of the pathogen and achieve early diagnosis of the disease.

[0025] Then, a kit is prepared, and the prepared antigen is combined with other related reagents into a kit. Other related reagents include PCR reagents and positive controls for laboratory use. The assembly of the kit requires strict control of the content and quality of each component to ensure that the kit has consistent performance and stability.

[0026] Next, the kit's quality control and performance evaluation are performed, and the kit's sensitivity, specificity, stability, and reproducibility are evaluated through a series of experiments and validation steps.

[0027] Finally, laboratory and clinical validation is carried out, and the prepared kit is applied to the detection of laboratory and clinical samples to evaluate its performance in actual applications. By comparing and analyzing with existing diagnostic methods, the accuracy and reliability of the kit in disease diagnosis are verified.

[0028] Furthermore, the evaluation platform construction and optimization module built a complete evaluation platform. By testing a large number of feline calicivirus disease samples, the performance of the platform was continuously optimized to ensure efficient, stable and reliable diagnostic capabilities in practical applications.

[0029] Furthermore, first, the evaluation platform construction and optimization module determine the evaluation indicators and standards, including the sensitivity, specificity, accuracy, repeatability and stability of the diagnostic reagents.

[0030] For the five characteristics of sensitivity, specificity, accuracy, repeatability and stability, mathematical models are established:

[0031]

[0032] in, are the sensitivity, specificity, accuracy, repeatability and stability of the samples respectively, which are column vectors. is the number of samples, is the sensitivity of the first sample, is the specificity of the first sample, is the accuracy of the first sample, is the repeatability of the first sample, is the stability of the first sample, is the sensitivity of the second sample, is the specificity of the second sample, is the accuracy of the second sample, is the repeatability of the second sample, is the stability of the second sample, For the The sensitivity of the samples, For the The specificity of each sample, For the The accuracy of the samples, For the The repeatability of the samples, For the The stability of the samples, For the The sensitivity of the samples, For the The specificity of each sample, For the The accuracy of the samples, For the The repeatability of the samples, For the The stability of the samples;

[0033] Then perform mutation-local crossover-global crossover transformation on the sample. The steps are as follows:

[0034] (1) Variation

[0035]

[0036] in, is the mutation probability, represents the sample of the tth iteration under the jth group of samples, where , for By probability After the mutation, is the mutation threshold;

[0037] (2) Cross with the individual optimal sample

[0038] Then, the mutated samples are cross-operated with the individual optimal samples, and we have:

[0039]

[0040] in, Indicates Group samples, is the probability of crossing with the individual optimal sample, Indicated in Middle Line A sample of columns, is the lower limit of the individual optimal sample crossing threshold, is the upper limit of the individual optimal sample crossover threshold, is the individual optimal sample score, for By probability Sample after crossover;

[0041] (3) Cross with the global optimal sample

[0042] Then Perform cross operation with the global optimal sample, we have:

[0043]

[0044] in, is the probability of crossing with the global optimal sample, is the global optimal sample score, for By probability Samples after crossover.

[0045] Further, construct performance indicator function To express the performance of the evaluation platform, we have:

[0046]

[0047] in, , , , , are all undetermined coefficients. The expression contains polynomial terms, reciprocal terms, exponential terms and logarithmic terms, which ensures the robustness of the model. The parameter vector is introduced , represents the parameters of the evaluation platform, assuming that the optimal parameter vector is , so that the performance index function Minimize, we have:

[0048]

[0049] Based on a combination of neural networks and gradient descent, we optimize the parameter vector , define the neural network output as , is the parameter vector and parameter vector Function: ,in is a neural network model, defining the loss function For parameter vector The gradient is:

[0050]

[0051] in, is the loss function The gradient of is the true output for each sample, In order to reduce the loss function, the parameter vector To update:

[0052]

[0053] in, is the parameter vector before updating, is the updated parameter vector, is the learning rate.

[0054] Furthermore, the evaluation platform construction and optimization module builds an evaluation platform, which includes laboratory equipment, test kits, and experimental operation procedures. According to the evaluation indicators and standards, appropriate laboratory equipment and test kits are selected, and corresponding experimental operation procedures are designed. At the same time, a quality management system needs to be established to ensure the accuracy and reliability of experimental data.

[0055] Next, a preliminary evaluation was conducted using existing feline calicivirus disease samples to conduct preliminary testing and evaluation of the evaluation platform. The sensitivity and specificity of the platform were evaluated by detecting pathogens in the samples; the repeatability and stability of the platform were evaluated by repeatedly testing the same sample; and the accuracy of the platform was evaluated by comparative analysis with existing diagnostic methods.

[0056] Then, the evaluation platform is optimized. According to the results of the preliminary evaluation, the evaluation platform is optimized, mainly including optimizing the formula and preparation process of the test kit, optimizing the experimental operation process, optimizing the experimental conditions and parameters. Through a series of experiments and verification steps, the performance of the platform is continuously optimized to improve its diagnostic ability and practicality.

[0057] Next, we will conduct scalability verification using more feline calicivirus disease samples to verify the scalability of the optimized evaluation platform. By testing samples from different sources and of different natures, we will verify the applicability and stability of the platform in different situations. At the same time, we need to conduct statistical analysis on the results of the scalability verification to evaluate the performance of the platform in actual applications.

[0058] Finally, establish a quality control system for the evaluation platform. Establish a complete quality control system, including internal quality control and external quality control. Ensure the performance of the evaluation platform and the reliability of the data through regular quality control testing and inter-laboratory comparisons. At the same time, establish standardized operating procedures and recording systems to facilitate real-time monitoring and traceability of the performance of the evaluation platform.

[0059] The beneficial effects of the invention are as follows: the invention adopts genetic engineering technology and immunological methods to prepare monoclonal antibodies, and fixes them on specific materials to construct a stable antibody immobilization platform. Compared with traditional polyclonal antibodies, monoclonal antibodies have higher specificity and stability, and can more accurately identify target antigens. At the same time, the use of immobilization platform technology to fix antibodies on specific materials not only improves the stability and repeatability of antibodies, but also facilitates the preparation and storage of reagents, thereby greatly improving the quality and reliability of diagnostic reagents; the invention prepares reagents with high specificity and sensitivity by selecting suitable antigens and preparation methods, which can accurately and quickly detect the presence of pathogens related to feline calicivirus disease, and provide important support for the early diagnosis and treatment of the disease. The invention constructs a complete evaluation platform. By testing a large number of feline calicivirus disease samples, The performance of the platform is continuously optimized. Through strict quality control and performance evaluation, it is ensured that the diagnostic reagents have efficient, stable and reliable diagnostic capabilities in practical applications, and the accuracy and reliability of diagnosis are improved. In the evaluation platform construction and optimization module, a mathematical model is established for the sensitivity, specificity, accuracy, repeatability and stability of the diagnostic reagents, and standardization and normalization are performed on samples of different dimensions. The innovation lies in that in order to escape the local optimal solution, the present invention adopts mutation and crossover operations. The difference from the traditional genetic algorithm is that the present invention further subdivides the crossover into crossover with individual optimal samples and crossover with global optimal samples, which fully guarantees the richness and diversity of samples in the sample pool, and is conducive to the system's exploration of the global optimal solution. In order to quantify the performance of the evaluation system provided by the present invention, the present invention constructs a performance indicator function , and fully considers the complex relationship between sample data, including polynomial terms, reciprocal terms, exponential terms and logarithmic terms, ensuring the robustness of the model and improving the universality of the platform. It can be applied to the diagnosis and treatment of other animal infectious diseases. In terms of market prospects, as people pay more attention to pet health, the pet diagnosis market shows a rapid growth trend. The present invention has a broad market application prospect. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] The invention is further illustrated by the accompanying drawings, but the embodiments in the accompanying drawings do not constitute any limitation to the invention. A person skilled in the art can obtain other drawings based on the following drawings without creative work.

[0061] Figure 1 It is a schematic diagram of the structure of the present invention. DETAILED DESCRIPTION

[0062] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0063] A feline calicivirus monoclonal antibody and an evaluation platform for its application in a feline calicivirus disease diagnostic reagent, comprising a feline calicivirus monoclonal antibody preparation module, an antibody identification and verification module, an antibody immobilization platform module, a feline calicivirus disease diagnostic reagent preparation module and an evaluation platform construction and optimization module, wherein the feline calicivirus monoclonal antibody preparation module prepares highly specific and high-affinity antibodies through genetic engineering technology; the antibody identification and verification module ensures that the antibodies have high sensitivity and specificity; the antibody immobilization platform module fixes the antibodies on specific materials for reagent preparation; the feline calicivirus disease diagnostic reagent preparation module constructs efficient and accurate diagnostic reagents; and the evaluation platform construction and optimization module evaluates samples.

[0064] Specifically, the feline calicivirus monoclonal antibody preparation module uses genetic engineering technology to prepare highly specific and high-affinity monoclonal antibodies.

[0065] Specifically, first, it is necessary to select appropriate feline calicivirus-related proteins as antigens, including surface proteins or structural proteins associated with viral infection, which are highly immunogenic. The genome of feline calicivirus has been widely studied, so a suitable gene sequence is selected for cloning and expression.

[0066] Specifically, the selected feline calicivirus gene is inserted into an expression vector using recombinant DNA technology. The expression vector usually contains an appropriate promoter and terminator, as well as an appropriate host cell selection marker gene for expression. The expression vector is introduced into the host cell, and the target protein is expressed using the host cell's biosynthetic mechanism.

[0067] Specifically, after protein expression and purification, affinity purification technology is used to purify the target protein using protein A / G agarose and metal chelate chromatography to obtain a relatively pure target protein, which is used to immunize mice to prepare monoclonal antibodies.

[0068] Specifically, mice are used for immunization, the purified target protein is mixed with an appropriate immune adjuvant and injected into the mice to stimulate them to produce antibodies. In order to enhance the immune effect, multiple immunizations are required, with intervals of several weeks or months.

[0069] Specifically, the antiserum produced by the mice is collected, and after the immunization cycle is completed, serum samples are collected from the blood of the mice, and the serum contains the polyclonal antibodies produced by the stimulation.

[0070] Specifically, monoclonal antibodies are prepared through cell fusion technology, in which the B cells of immunized mice are fused with cancer cells to form hybridoma cells. These hybridoma cells have the ability of B cells to produce antibodies and the unlimited proliferation ability of cancer cells. After screening and cultivation, hybridoma cell lines that produce monoclonal antibodies are obtained.

[0071] Specifically, the antibody identification and validation module ensures that the prepared monoclonal antibodies have high sensitivity and specificity, so that they can accurately identify the target antigen and play a role in diagnostic reagents.

[0072] Specifically, the prepared monoclonal antibodies are subjected to preliminary identification, including Western blot (immunoblotting) and ELISA (enzyme-linked immunosorbent assay), to verify the specific binding of the antibody to the target antigen.

[0073] Specifically, in a Western blot experiment, the target protein first needs to be separated and transferred to a membrane, then reacted with the prepared monoclonal antibody, and the protein-antibody binding signal is detected by chemiluminescence or staining methods;

[0074] Specifically, in an ELISA experiment, the target antigen is adsorbed on a microplate, then reacted with an antibody, and the binding of the antibody is detected by an enzyme-labeled secondary antibody or a substrate staining method.

[0075] Specifically, the affinity of the antibody is measured. Affinity refers to the strength of the binding between the antibody and the antigen, which directly affects its effect in the diagnostic reagent. The present invention adopts commonly used methods including surface ion resonance and biochromatography technology, which can monitor the interaction process between the antibody and the antigen in real time, thereby accurately measuring its affinity constant (KA) and dissociation constant (KD) and evaluating the binding characteristics between the antibody and the antigen.

[0076] Specifically, the specificity of the antibody is evaluated. Specificity refers to the ability of the antibody to bind to the target antigen without cross-reacting with other non-specific components. In order to evaluate the specificity of the antibody, a cross-reaction experiment is required to react the antibody with related non-target antigens to observe whether a specific binding signal is generated.

[0077] Specifically, the specificity of the antibody is further verified using tissue sections or cell line experimental models.

[0078] Specifically, the stability test of the antibody is performed, as the stability of the antibody directly affects its service life and storage conditions in the diagnostic reagent.

[0079] Specifically, the present invention adopts commonly used stability tests, including thermal stability test, freeze-thaw stability test and long-term storage stability test, which can simulate the stability performance of antibodies under different environmental conditions and evaluate their reliability in practical applications.

[0080] Specifically, actual sample testing and verification of antibodies will be carried out, and antibodies will be tested and verified using real samples of wild-type viruses and clinical samples. The performance in actual applications will be evaluated, and the accuracy and sensitivity of antibodies in disease diagnosis will be verified by comparative analysis with existing diagnostic methods.

[0081] Specifically, the antibody immobilization platform module fixes the prepared monoclonal antibody on a specific material surface to form a stable antibody immobilization platform for the preparation of diagnostic reagents for feline calicivirus disease.

[0082] Specifically, a suitable immobilization material is selected. The selection of the immobilization material needs to take into account its immobilization effect on the antibody, stability, biocompatibility and convenience of the preparation process.

[0083] Specifically, the immobilization material includes polyvinyl alcohol, polyacrylate, glass sheet, and metal material. According to the actual needs of the reagent, a suitable immobilization material is selected for subsequent treatment.

[0084] Specifically, the immobilized material is subjected to surface treatment, the purpose of which is to increase the active functional groups on the surface of the immobilized material and improve the adsorption efficiency and fixation effect of the antibody.

[0085] Specifically, the surface treatment methods include physical adsorption, chemical cross-linking, and covalent bonding. The surface of the immobilized material is treated with a chemical cross-linking agent (including nitrates, formaldehyde) or an activator (including EDC / NHS) to have more active groups for covalent bonding with antibodies.

[0086] Specifically, the prepared monoclonal antibody is fixed on the surface treated immobilized material. The method of fixing the antibody is selected according to the characteristics of the immobilized material and the actual needs of the reagent. The antibody solution is directly added dropwise to the surface treated immobilized material, and the antibody is uniformly adsorbed on the surface of the material by standing and rotating.

[0087] Specifically, the immobilized antibody is subjected to quality control and stability evaluation. The activity and binding efficiency of the immobilized antibody are detected to evaluate its fixation effect and stability. The quality control methods include ELISA and immunofluorescence.

[0088] Specifically, the preparation process of the immobilization platform is optimized, and the preparation process of the immobilization platform is optimized according to the results of quality control and stability evaluation.

[0089] Specifically, the stability of the immobilization platform is improved by adjusting the surface treatment method of the immobilization material, the antibody immobilization conditions, and the stability treatment steps after immobilization.

[0090] Specifically, the feline calicivirus disease diagnostic reagent preparation module is used to construct efficient and accurate diagnostic reagents for the detection and diagnosis of feline calicivirus disease.

[0091] Specifically, appropriate antigens are selected, and the diagnostic reagents for feline calicivirus disease contain antigens associated with multiple pathogens, including feline blood-type bacilli, feline erythrozoon and feline plasmodium.

[0092] Specifically, antigens are prepared, and selected antigens are expressed and purified through genetic engineering technology and in vitro culture technology. For diagnostic reagents for feline calicivirus disease, multiple antigens need to be prepared simultaneously.

[0093] Specifically, highly sensitive and specific detection methods are selected, including PCR (polymerase chain reaction), PCR-RFLP (PCR-Restriction Fragment Length Polymorphism), and real-time fluorescence quantitative PCR, to quickly and accurately detect nucleic acids of pathogens and achieve early diagnosis of diseases;

[0094] Specifically, a kit is prepared, and the prepared antigen is combined with other related reagents to form a kit, and other related reagents include PCR reagents and positive controls for easy use in the laboratory.

[0095] Specifically, the assembly of the kit requires strict control of the content and quality of each component to ensure that the kit has consistent performance and stability;

[0096] Specifically, the quality control and performance evaluation of the kit are carried out, and the sensitivity, specificity, stability and repeatability performance of the kit are evaluated through a series of experiments and verification steps.

[0097] Specifically, laboratory and clinical validation will be carried out, and the prepared test kits will be applied to the detection of laboratory and clinical samples to evaluate their performance in actual applications. By comparing and analyzing with existing diagnostic methods, the accuracy and reliability of the test kits in disease diagnosis will be verified.

[0098] Specifically, the evaluation platform construction and optimization module has built a complete evaluation platform. By testing a large number of feline calicivirus disease samples, the performance of the platform is continuously optimized to ensure efficient, stable and reliable diagnostic capabilities in practical applications.

[0099] Specifically, the evaluation platform construction and optimization module determines the evaluation indicators and standards, including the sensitivity, specificity, accuracy, repeatability and stability of the diagnostic reagents.

[0100] Specifically, for the five characteristics of sensitivity, specificity, accuracy, repeatability, and stability, mathematical models are established as follows:

[0101]

[0102] in, are the sensitivity, specificity, accuracy, repeatability and stability of the samples respectively, which are column vectors. is the number of samples, is the sensitivity of the first sample, is the specificity of the first sample, is the accuracy of the first sample, is the repeatability of the first sample, is the stability of the first sample, is the sensitivity of the second sample, is the specificity of the second sample, is the accuracy of the second sample, is the repeatability of the second sample, is the stability of the second sample, For the The sensitivity of the samples, For the The specificity of each sample, For the The accuracy of the samples, For the The repeatability of the samples, For the The stability of the samples, For the The sensitivity of the samples, For the The specificity of each sample, For the The accuracy of the samples, For the The repeatability of the samples, For the The stability of the samples.

[0103] Specifically, the samples are transformed into mutation-local crossover-global crossover. The steps are as follows:

[0104] (1) Variation

[0105]

[0106] in, is the mutation probability, represents the sample of the tth iteration under the jth group of samples, where , for By probability After the mutation, is the mutation threshold;

[0107] (2) Cross with the individual optimal sample

[0108] Then, the mutated samples are cross-operated with the individual optimal samples, and we have:

[0109]

[0110] in, Indicates Group samples, is the probability of crossing with the individual optimal sample, Indicated in Middle Line A sample of columns, is the lower limit of the individual optimal sample crossing threshold, is the upper limit of the individual optimal sample crossover threshold, is the individual optimal sample score, for By probability Sample after crossover;

[0111] (3) Cross with the global optimal sample

[0112] Then Performing cross operation with the global optimal sample, we have:

[0113]

[0114] in, is the probability of crossing with the global optimal sample, is the global optimal sample score, for By probability Samples after crossover.

[0115] Specifically, construct a performance indicator function To express the performance of the evaluation platform, we have:

[0116]

[0117] in, , , , , are all undetermined coefficients. The expression contains polynomial terms, reciprocal terms, exponential terms and logarithmic terms, which ensures the robustness of the model. The parameter vector is introduced , represents the parameters of the evaluation platform, assuming that the optimal parameter vector is , so that the performance index function Minimize, we have:

[0118]

[0119] Based on a combination of neural networks and gradient descent, we optimize the parameter vector , define the neural network output as , is the parameter vector and parameter vector Function: ,in is a neural network model, defining the loss function For parameter vector The gradient is:

[0120]

[0121] in, is the loss function The gradient of is the true output for each sample, In order to reduce the loss function, the parameter vector To update:

[0122]

[0123] in, is the parameter vector before updating, is the updated parameter vector, is the learning rate.

[0124] Specifically, the evaluation platform construction and optimization module builds an evaluation platform, which includes laboratory equipment, test kits, and experimental operation procedures. According to the evaluation indicators and standards, appropriate laboratory equipment and test kits are selected, and corresponding experimental operation procedures are designed.

[0125] Specifically, it is necessary to establish a quality management system to ensure the accuracy and reliability of experimental data.

[0126] Specifically, a preliminary evaluation was conducted using existing feline calicivirus disease samples to conduct preliminary testing and evaluation of the evaluation platform. The sensitivity and specificity of the platform were evaluated by detecting pathogens in the samples; the repeatability and stability of the platform were evaluated by repeatedly testing the same sample; and the accuracy of the platform was evaluated by comparative analysis with existing diagnostic methods.

[0127] Specifically, the evaluation platform is optimized based on the results of the preliminary evaluation, mainly including optimizing the formula and preparation process of the test kit, optimizing the experimental operation process, optimizing the experimental conditions and parameters, and through a series of experiments and verification steps, continuously optimizing the performance of the platform to improve its diagnostic capabilities and practicality.

[0128] Specifically, scalability verification is carried out by using more feline calicivirus disease samples to verify the scalability of the optimized evaluation platform. By testing samples from different sources and of different properties, the applicability and stability of the platform in different situations are verified. At the same time, it is necessary to conduct statistical analysis on the results of the scalability verification to evaluate the performance of the platform in actual applications.

[0129] Specifically, a quality control system for the evaluation platform should be established, and a complete quality control system should be established, including internal quality control and external quality control. Through regular quality control testing and inter-laboratory comparisons, the performance of the evaluation platform and the reliability of the data can be ensured.

[0130] Specifically, a standardized operating procedure and recording system should be established to enable real-time monitoring and traceability of the performance of the evaluation platform.

[0131] The beneficial effects of the invention are as follows: the invention adopts genetic engineering technology and immunological methods to prepare monoclonal antibodies, and fixes them on specific materials to construct a stable antibody immobilization platform. Compared with traditional polyclonal antibodies, monoclonal antibodies have higher specificity and stability, and can more accurately identify target antigens. At the same time, the use of immobilization platform technology to fix antibodies on specific materials not only improves the stability and repeatability of antibodies, but also facilitates the preparation and storage of reagents, thereby greatly improving the quality and reliability of diagnostic reagents; the invention prepares reagents with high specificity and sensitivity by selecting suitable antigens and preparation methods, which can accurately and quickly detect the presence of pathogens related to feline calicivirus disease, and provide important support for the early diagnosis and treatment of the disease. The invention constructs a complete evaluation platform. By testing a large number of feline calicivirus disease samples, The performance of the platform is continuously optimized. Through strict quality control and performance evaluation, it is ensured that the diagnostic reagents have efficient, stable and reliable diagnostic capabilities in practical applications, and the accuracy and reliability of diagnosis are improved. In the evaluation platform construction and optimization module, a mathematical model is established for the sensitivity, specificity, accuracy, repeatability and stability of the diagnostic reagents, and standardization and normalization are performed on samples of different dimensions. The innovation lies in that in order to escape the local optimal solution, the present invention adopts mutation and crossover operations. The difference from the traditional genetic algorithm is that the present invention further subdivides the crossover into crossover with individual optimal samples and crossover with global optimal samples, which fully guarantees the richness and diversity of samples in the sample pool, and is conducive to the system's exploration of the global optimal solution. In order to quantify the performance of the evaluation system provided by the present invention, the present invention constructs a performance indicator function , and fully considers the complex relationship between sample data, including polynomial terms, reciprocal terms, exponential terms and logarithmic terms, ensuring the robustness of the model and improving the universality of the platform. It can be applied to the diagnosis and treatment of other animal infectious diseases. In terms of market prospects, as people pay more attention to pet health, the pet diagnosis market shows a rapid growth trend. The present invention has a broad market application prospect.

[0132] Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A feline calicivirus disease diagnostic reagent evaluation platform, characterized in that: It includes a feline calicivirus monoclonal antibody preparation module, an antibody identification and verification module, an antibody immobilization platform module, a feline calicivirus disease diagnostic reagent preparation module, and an evaluation platform construction and optimization module. The feline calicivirus monoclonal antibody preparation module prepares highly specific and high-affinity antibodies through genetic engineering technology; the antibody identification and verification module ensures that the antibodies have high sensitivity and specificity; the antibody immobilization platform module fixes the antibodies on specific materials for reagent preparation; the feline calicivirus disease diagnostic reagent preparation module constructs efficient and accurate diagnostic reagents; and the evaluation platform construction and optimization module evaluates the samples. First, the evaluation platform construction and optimization module determines the evaluation indicators and standards, including the sensitivity, specificity, accuracy, repeatability, and stability of the diagnostic reagents; For the five characteristics of sensitivity, specificity, accuracy, repeatability and stability, mathematical models are established: Among them, X G1 ,X G2 ,X G3 ,X G4 ,X G5 are the sensitivity, specificity, accuracy, repeatability, and stability of the samples, respectively. They are column vectors, m is the number of samples, and X 11 is the sensitivity of the first sample, X 12 is the specificity of the first sample, X 13 is the accuracy of the first sample, X 14 is the repeatability of the first sample, X 15 is the stability of the first sample, X 21 is the sensitivity of the second sample, X 22 is the specificity of the second sample, X 23 is the accuracy of the second sample, X 24 is the repeatability of the second sample, X 25 is the stability of the second sample, X i1 is the sensitivity of the i-th sample, X i2 is the specificity of the i-th sample, X i3 is the accuracy of the i-th sample, X i4 is the repeatability of the i-th sample, X i5 is the stability of the i-th sample, X m1 is the sensitivity of the mth sample, X m2 is the specificity of the mth sample, X m3 is the accuracy of the mth sample, X m4 is the repeatability of the mth sample, X m5 is the stability of the mth sample; Then perform mutation-local crossover-global crossover transformation on the sample. The steps are as follows: (1) Variation Among them, P M is the mutation probability, represents the sample of the tth iteration under the jth group of samples, where for According to probability P M The mutated sample, θ M is the mutation threshold; (2) Cross-reference with the individual optimal sample Then, the mutated samples are cross-operated with the individual optimal samples, and we have: in, represents the jth group of samples, is the probability of crossing with the individual optimal sample, X ij represents the sample in the i-th row and j-th column in X, θ c\below is the lower limit of the individual optimal sample crossing threshold, θ c\above is the upper limit of the individual optimal sample crossover threshold, F p is the individual optimal sample score, for By probability Sample after crossover; (3) Cross with the global optimal sample Then Performing cross operation with the global optimal sample, we have: in, is the probability of crossing with the global optimal sample, F g is the global optimal sample score, for By probability Sample after crossover; Constructing performance indicator functions To express the performance of the evaluation platform, we have: Among them, a0, a i , b i 、c i d i All are undetermined coefficients. The expression contains polynomial terms, reciprocal terms, exponential terms and logarithmic terms, which ensures the robustness of the model. The parameter vector Γ is introduced to represent the parameters of the evaluation platform. Assume that the optimal parameter vector is Γ * , so that the performance index function Minimize, we have: Based on the combination of neural network and gradient descent, the parameter vector Γ is optimized. The output of the neural network is defined as y, which is a function of the parameter vector z and the parameter vector Γ: y = g(z, Γ), where g is the neural network model, and the gradient of the loss function Loss to the parameter vector Γ is defined as: in, is the gradient of the loss function Loss, is the true output for each sample, In order to reduce the loss function, the parameter vector Γ is updated: Among them, Γ(t) is the parameter vector before updating, Γ(t+1) is the parameter vector after updating, and η is the learning rate.

2. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 1, characterized in that: The feline calicivirus monoclonal antibody preparation module uses genetic engineering technology to prepare highly specific and high-affinity monoclonal antibodies.

3. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 1, characterized in that: The antibody identification and validation module ensures that the prepared monoclonal antibodies have high sensitivity and specificity, so that they can accurately identify the target antigen and play a role in diagnostic reagents.

4. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 1, characterized in that: The antibody immobilization platform module fixes the prepared monoclonal antibody on a specific material surface to form a stable antibody immobilization platform for the preparation of diagnostic reagents for feline calicivirus disease.

5. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 1, characterized in that: The feline calicivirus disease diagnostic reagent preparation module is used to construct efficient and accurate diagnostic reagents for the detection and diagnosis of feline calicivirus disease.

6. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 1, characterized in that: The evaluation platform construction and optimization module has built a complete evaluation platform. By testing a large number of feline calicivirus disease samples, the performance of the platform is continuously optimized to ensure efficient, stable and reliable diagnostic capabilities in practical applications.

7. A feline calicivirus disease diagnostic reagent evaluation platform according to claim 6, characterized in that: Evaluation platform construction and optimization module Build an evaluation platform, which includes laboratory equipment, test kits, and experimental operation procedures. According to the evaluation indicators and standards, select appropriate laboratory equipment and test kits, and design corresponding experimental operation procedures. At the same time, a quality management system needs to be established to ensure the accuracy and reliability of experimental data; Next, a preliminary evaluation was conducted using existing feline calicivirus disease samples to conduct preliminary testing and evaluation of the evaluation platform. The sensitivity and specificity of the platform were evaluated by detecting pathogens in the samples. The repeatability and stability of the platform were evaluated by repeatedly testing the same sample. Evaluate the accuracy of the platform through comparative analysis with existing diagnostic methods; Then, optimize the evaluation platform. According to the results of the preliminary evaluation, optimize the evaluation platform, mainly including optimizing the formula and preparation process of the kit, optimizing the experimental operation process, optimizing the experimental conditions and parameters. Through a series of experiments and verification steps, continuously optimize the performance of the platform to improve its diagnostic ability and practicality; Next, we will conduct scalability verification using more feline calicivirus disease samples to verify the scalability of the optimized evaluation platform. By testing samples from different sources and with different properties, we will verify the applicability and stability of the platform in different situations. At the same time, we need to conduct statistical analysis on the results of the scalability verification to evaluate the performance of the platform in actual applications. Finally, establish a quality control system for the evaluation platform. Establish a complete quality control system, including internal quality control and external quality control. Ensure the performance of the evaluation platform and the reliability of the data through regular quality control testing and inter-laboratory comparisons. At the same time, establish standardized operating procedures and recording systems to facilitate real-time monitoring and traceability of the performance of the evaluation platform.